Nemolizumab showed statistically significant improvements in the coprimary endpoints of IGA success and EASI-75 compared with placebo. The Food and Drug Administration (FDA) has approved Nemluvio ® ...

Please provide your email address to receive an email when new articles are posted on . Ebglyss is a targeted interleukin-13 inhibitor approved for the treatment of moderate-to-severe atopic ...

The Adbry autoinjector is for use in adults only. A new single-dose autoinjector presentation of Adbry ® (tralokinumab-ldrm) is now available for use in the treatment of moderate to severe atopic ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Injections included six for APG777, 11 for ...

How do dermatologists diagnose atopic dermatitis? To diagnose atopic dermatitis, also called eczema, a board-certified dermatologist carefully examines your (or your child's) skin and asks questions. ...

Interim clinical data from APG777 Phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of approximately 75 days with a potentially best-in-class profile 16-week ...

Among EBGLYSS Week 16 responders from the monotherapy trials, 50% achieved highest bar of complete skin clearance (EASI 100 or IGA 0) and 87% achieved almost-clear skin (EASI 90) at three years with ...

(RTTNews) - Eli Lilly and Co. (LLY) announced that its Ebglyss monotherapy monthly injection demonstrated sustained and deep responses in patients with moderate-to-severe atopic dermatitis over three ...

Atopic dermatitis involves complex immune and neuronal pathways, with biologics targeting IL-4, IL-13, and IL-31 showing promise in treatment. Diagnostic and treatment strategies must consider skin ...

Elanco Animal Health Incorporated (NYSE: ELAN) today announced the phased launch of Befrena™ (tirnovetmab), a new anti-IL-31 ...

MedPage Today brought together three expert leaders for a virtual roundtable discussion on atopic dermatitis: Moderator Peter Lio, MD, of Northwestern University Feinberg School of Medicine in Chicago ...